Difference between revisions of "PEComa"
Jump to navigation
Jump to search
(Created page with "{| class="wikitable" style="text-align:center; width:50%;" !colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor''' |- |s...") |
Warner-admin (talk | contribs) m (Text replacement - "|Phase II" to "|Phase 2") |
||
Line 31: | Line 31: | ||
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601264/ Wagner et al. 2021 (AMPECT)] | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601264/ Wagner et al. 2021 (AMPECT)] | ||
|2016-2018 | |2016-2018 | ||
− | | style="background-color:#91cf61" |Phase | + | | style="background-color:#91cf61" |Phase 2 (RT) |
|- | |- | ||
|} | |} |
Revision as of 17:54, 12 February 2022
Section editor | |
---|---|
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN ![]() |
Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
1 variants on this page
|
All lines of therapy
nab-Sirolimus monotherapy
back to top |
Regimen
FDA-recommended dose |
Study | Years of enrollment | Evidence |
---|---|---|
Wagner et al. 2021 (AMPECT) | 2016-2018 | Phase 2 (RT) |
Targeted therapy
- Sirolimus protein-bound particles (Fyarro) 100 mg/m2 IV once per day on days 1 & 8
21-day cycles
References
- AMPECT: Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, Cranmer L, Gordon EM, Hornick JL, Du H, Grigorian B, Schmid AN, Hou S, Harris K, Kwiatkowski DJ, Desai NP, Dickson MA. nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. J Clin Oncol. 2021 Nov 20;39(33):3660-3670. Epub 2021 Oct 12. link to original article contains verified protocol link to PMC article PubMed NCT02494570